Reapplix ApS (Reapplix), developers of the unique LeucoPatch active wound therapy, have appointed Graeme Brookes as Chief Executive Officer. Graeme’s appointment significantly strengthens the commercial capabilities of the management team and provides increased emphasis on implementing this promising technology into clinical use. Graeme joins founders Niels Erik Holm and Rasmus Lundquist on the senior leadership team, with responsibility for overall direction and strategy and with a particular emphasis on preparing for the future commercialisation of the LeucoPatch technology once the ongoing randomised clinical trial is completed. A key focus for Graeme will also be the regulatory and reimbursement strategies necessary to underpin the commercial potential of this promising technology. Graeme joins Reapplix from Stanmore Implants, a UK based orthopaedic company, where he was Global Vice President for Product Development and Product Marketing. Prior to this, he was the CEO at Acrobot, where he built a robotic technology company, and then managed its trade sale to Stanmore Implants. He has also held senior roles at Johnson and Johnson and at Advanced Medical Solutions, where he spent five years in wound care sales and marketing.
Peter Hentschel, Chairman of Reapplix, said:
“We are very pleased to welcome Graeme to Reapplix at this important time in the growth of the company. Graeme has a wealth of experience that will be crucial in defining and executing our future strategies to ensure that we continue to build on the significant value created so far.”
Niels Erik Holm, who now takes up the role of COO, and CSO Rasmus Lundquist stated:
“The arrival of Graeme means that we can apply increased focus to our key clinical and product development activities whilst documenting the clinical benefits of the unique technology. In addition this enables us to continue focusing on our essential cooperation with the clinical professionals working with our product. We welcome Graeme to the management team and look forward to continuing to develop Reapplix further.”
Graeme Brookes, CEO
+45 53 77 74 47
Reapplix is a Danish medtech company, founded in 2008 by Niels Erik Holm and Rasmus Lundquist. Reapplix’s core technology is based on the development of blood-based treatments for patients. The company’s first patented product is LeucoPatch® for the treatment of diabetic foot ulcers. Reapplix is a privately-held company backed by three leading Danish investors, SEED Capital, Novo Seeds and Vækstfonden (The Danish Growth Fund), and has been supported by Markedsmodningsfonden.